Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/150.1)
-
Patent number: 8591899Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.Type: GrantFiled: March 22, 2010Date of Patent: November 26, 2013Assignee: State of Israel, Represented by Prime Minister's Office, Israel Institute for Biological ResearchInventors: Avigdor Shafferman, Ofer Cohen, Theodor Chitlaru, Sagit Sela-Abramovich, Orit Gat
-
Patent number: 8586046Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.Type: GrantFiled: December 29, 2011Date of Patent: November 19, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Joel Barry Baseman, Thirumalai Regasamy Kannan
-
Patent number: 8574853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: December 2, 2011Date of Patent: November 5, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Patent number: 8546093Abstract: The present invention relates to an antibody against a protein specifically expressed in methicillin-resistant strains of Staphylococcus aureus (MRSA), and a method and a kit for detecting MRSA. The present invention enables a fast and accurate detection of MRSA by using both a PBP2a-specific antibody for the detection of PBP2a and a Protein A-specific antibody for the detection of Protein A.Type: GrantFiled: June 24, 2009Date of Patent: October 1, 2013Assignee: Dinona Inc.Inventors: Hyung-Geun Song, Sang-Soon Yoon, Hae-Jung Kim, Gil-Yong Jee, Mi-Hyang Shin, Yu-Ri Moon
-
Patent number: 8541179Abstract: The present invention provides a method for specifically detecting a Mycobacterium tuberculosis complex-specific secretory protein MPT64 antigen in a biological sample, whereby diagnosis of infection with Mycobacterium tuberculosis is carried out rapidly and safely with higher accuracy than before. An antibody that recognizes an epitope for MPB64 located in any one of amino acid sequences of SEQ ID NOS: 2 to 4, particularly a monoclonal antibody was obtained. Thus, an immunoassay using the antibody, particularly a sandwich immunoassay using first and second antibodies to MPB64, particularly an immunochromatographic assay and an immunochromatographic test strip are provided. A biological sample can be rapidly subjected to the immunoassay without culturing or after culturing for a time before Mycobacterium tuberculosis complex bacteria in the sample substantially start to grow.Type: GrantFiled: December 19, 2008Date of Patent: September 24, 2013Assignee: BL Co., Ltd.Inventor: Yasuharu Namba
-
Publication number: 20130236469Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: May 25, 2011Publication date: September 12, 2013Applicant: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 8512754Abstract: A composition comprising a glassified, stabilized particle preparation having a low water activity (between about 0.1 and 0.9) is provided. The preparations provide improved products with enhanced storage stability, less expensive cost of processing, and extended shelf life. The glassified, stabilized particle preparations are particularly efficacious in the preparation of perishable products, especially pharmaceutical agents, such as human blood and blood products (e.g., red blood cells). A single emulsion process comprising a 2-phase system for preserving food and pharmaceutical products is also provided. Stabilized biological products as glassified beads are also provided, as well as a method for rehydrating and/or reconstituting the glassified beads to provide useful and fully active reconstituted and/or rehydrated materials is also presented.Type: GrantFiled: September 2, 2011Date of Patent: August 20, 2013Inventor: David Needham
-
Patent number: 8501182Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: November 19, 2009Date of Patent: August 6, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Patent number: 8491907Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: GrantFiled: July 13, 2010Date of Patent: July 23, 2013Assignee: Amgen, Inc.Inventor: John R. Schreiber
-
Patent number: 8475798Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.Type: GrantFiled: June 16, 2006Date of Patent: July 2, 2013Assignees: Inhibitex, Inc., The Texas A&M University SystemInventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
-
Patent number: 8470339Abstract: The present invention discloses new antigens of Mycobacterium avium subsp. paratuberculosis, antigenic compositions comprising at least two of said antigens, as well as epitopes, antibodies or hypervariable fragments thereof and nucleotide sequences coding for them. The present invention also concerns their use in diagnosis and/or vaccination against Mycobacterium avium subsp. paratuberculosis, in mammals, and in particular in cattle, but also in sheep and caprines. The invention also concerns their potential application in diagnosis and/or vaccination against Crohn's disease in human.Type: GrantFiled: November 6, 2007Date of Patent: June 25, 2013Assignees: Universite de Mons, Cerva-Coda, Institut Scientifique de Sante PubliqueInventors: Baptiste Leroy, Ruddy Wattiez, Christiane A. J. Huygen, Virginie Roupie, Marc Govaert, Isabelle Georis
-
Patent number: 8431128Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: December 12, 2011Date of Patent: April 30, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
-
Patent number: 8420090Abstract: Isolated and/or recombinant adhesin polypeptides from Burkholderia pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such polypeptides are also provided. Such antibodies can be used to detect the presence of B. pseudomallei or B. mallei and in methods of treating or preventing Burkholderia infection.Type: GrantFiled: October 4, 2011Date of Patent: April 16, 2013Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National DefenceInventors: Chad Wesley Stratilo, Scott James Jager
-
Publication number: 20130084292Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.Type: ApplicationFiled: April 15, 2011Publication date: April 4, 2013Applicant: UNIVERSITE D'AUVERGNE CLERMONT IInventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
-
Patent number: 8404820Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 7, 2008Date of Patent: March 26, 2013Assignee: Medarex, Inc.Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
-
Publication number: 20130045211Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: ApplicationFiled: January 5, 2011Publication date: February 21, 2013Applicants: THE ROCKEFELLER UNIVERSITY, CONTRAFECT CORPORATIONInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
-
Patent number: 8377446Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: GrantFiled: December 16, 2011Date of Patent: February 19, 2013Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 8361441Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided.Type: GrantFiled: September 29, 2009Date of Patent: January 29, 2013Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yung-Luen Shih, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Patent number: 8337846Abstract: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.Type: GrantFiled: July 23, 2008Date of Patent: December 25, 2012Assignee: Sanofi Pasteur LimitedInventors: Martina Ochs, Roger Brookes, Robert Charlebois, Jeremy Yethon
-
Patent number: 8318438Abstract: We describe examples using aptamers for capturing and reporting the presence of a target, such as a pathogen. Examples described here include a set of aptamers that are specific to F. tularensisis. Other examples described here include an Aptamer-Linked Immobilized Sorbent Assay (ALISA) and dot blot assay. An example of a method provided here comprises: providing a set of DNA sequences that exhibit high binding affinity to target antigen, placing the DNA sequences in a sandwich aptamer-linked immobilized sorbent assay (ALISA), contacting the DNA sequences with a sample, and detecting whether the target is present in the sample. Some alternative implementations may include dot blots and different reporters. Quantum dot sandwich assays and quantum dot de-quenching reporters can be used.Type: GrantFiled: February 27, 2008Date of Patent: November 27, 2012Assignee: The United States of America as represented by the Secretary of the Air ForceInventors: Jeevalatha Vivekananda, Johnathan L. Kiel
-
Patent number: 8313730Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.Type: GrantFiled: October 31, 2011Date of Patent: November 20, 2012Inventors: Michael R. Simon, Mark Andrew Kroenke
-
Publication number: 20120288508Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: ApplicationFiled: June 7, 2012Publication date: November 15, 2012Applicants: MEDAREX, INC., UNIVERSITY OF MASSACHUSETTSInventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
-
Patent number: 8309090Abstract: Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same.Type: GrantFiled: September 3, 2009Date of Patent: November 13, 2012Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National DefenseInventor: Wei-Gang Hu
-
Publication number: 20120282268Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.Type: ApplicationFiled: January 19, 2010Publication date: November 8, 2012Inventors: Johannes Hübner, Christian Theilacker, Otto Holst, Zbigniew Kaczynski
-
Patent number: 8268316Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.Type: GrantFiled: March 10, 2006Date of Patent: September 18, 2012Assignee: Aprogen, IncInventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
-
Publication number: 20120230913Abstract: Provided herein, inter alia, are protein dispersions comprising dense protein nanoclusters and methods of making the. Upon dilution, the clusters may reversibly dissociate into native protein molecules with high biological activity. The viscosities of the nanocluster dispersions may be sufficiently low to allow small-volume subcutaneous injections.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicant: Board of Regents, The University of Texas SystemInventors: Keith P. Johnston, Jennifer A. Maynard, Andrea Miller, Brian Wilson, Thomas M. Truskett, Ameya Borwankar, Aileen Dinin
-
Patent number: 8263078Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: GrantFiled: September 5, 2008Date of Patent: September 11, 2012Assignees: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
-
Patent number: 8241631Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.Type: GrantFiled: May 19, 2011Date of Patent: August 14, 2012Assignee: Crucell Holland B.V.Inventors: Mark Throsby, Robert Arjen Kramer, Cornelis Adriaan De Kruif
-
Patent number: 8241857Abstract: To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.Type: GrantFiled: March 31, 2009Date of Patent: August 14, 2012Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Suguru Akamatsu, Yoko Saijo
-
Publication number: 20120201829Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.Type: ApplicationFiled: August 10, 2010Publication date: August 9, 2012Inventors: Michael Rudolf, Holger Koch
-
Publication number: 20120195907Abstract: The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.Type: ApplicationFiled: August 10, 2010Publication date: August 2, 2012Applicant: FUNDACAO OSWALDO CRUZInventors: Jose Procopio Moreno Senna, Joao Luiz Sampaio Queiroz, Nadia Maria Batoreu, Maria da Gloria Martins Teixeira
-
Publication number: 20120177650Abstract: A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.Type: ApplicationFiled: September 22, 2010Publication date: July 12, 2012Inventor: Thomas Julius Borody
-
Patent number: 8197816Abstract: The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.Type: GrantFiled: February 13, 2006Date of Patent: June 12, 2012Assignee: Kenta Biotech AGInventors: Alois B. Lang, Michael P. Horn, Martin A. Imboden, Adrian Zuercher
-
Patent number: 8192720Abstract: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.Type: GrantFiled: February 5, 2010Date of Patent: June 5, 2012Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, RenoInventors: Thomas Kozel, William Murphy, Suzanne Brandt, Bruce R. Blazar, Julie A. Lovchik, Peter Thorkildson, Ann Percival, C. Richard Lyons
-
Publication number: 20120121581Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of anti-botulism antibodies and an effective amount of a succinate buffer, an effective amount of arginine, wherein the antibodies are present in substantially equal concentrations and the pH of the formulation is between about 5 and about 6.5.Type: ApplicationFiled: September 2, 2010Publication date: May 17, 2012Inventors: SUSAN JOYCE BABUKA, MINGXIANG LI
-
Publication number: 20120114662Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: October 7, 2008Publication date: May 10, 2012Applicant: MEDAREX, INC.Inventors: Tibor KELER, Israel LOWY, Laura A. VITALE, Diann BLANSET, Mohan SRINIVASAN
-
Patent number: 8173130Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: GrantFiled: September 5, 2008Date of Patent: May 8, 2012Assignee: Inotek Pharmaceuticals CorporationInventors: Andrew L. Salzman, Kanneganti Murthy
-
Publication number: 20120107316Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for ?-1,6-glucan.Type: ApplicationFiled: December 20, 2011Publication date: May 3, 2012Inventors: Antonio CASSONE, Antonella Torosantucci
-
Publication number: 20120100151Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.Type: ApplicationFiled: May 18, 2010Publication date: April 26, 2012Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Knut Ohlsen, Udo Lorenz
-
Patent number: 8158125Abstract: B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune diseases and in the treatment of inflammatory and autoimmune diseases. Also encompassed are diagnostic uses of these antibodies, for identifying people at risk of developing arthritis or diabetes, and a method of monitoring progress of the disease conditions and disease prognosis.Type: GrantFiled: December 29, 2008Date of Patent: April 17, 2012Assignee: Hadasit Medical Research Services & Development Ltd.Inventors: Yaakov Naparstek, Rina Ulmansky, Yechezkei Kashi
-
Patent number: 8153132Abstract: Antibodies immunoreactive to mutant Pseudomonas HPPD are provided, and in an embodiment the mutant HPPD is one in which the wild-type HPPD is substituted at residue 336 with tryptophan for glycine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: October 30, 2009Date of Patent: April 10, 2012Assignee: MS Technologies, Inc.Inventors: Vaithilingam Sekar, Bruce Held, Kyu Chung, Paul F. Russell, Jr.
-
Publication number: 20120082677Abstract: Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies against: polymerase, plasmin activators and fibrin are found in the blood of hepatitis C infected patients.Type: ApplicationFiled: October 1, 2010Publication date: April 5, 2012Inventor: Sherif Salah Abdul Aziz
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8142780Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.Type: GrantFiled: August 31, 2010Date of Patent: March 27, 2012Assignee: STROX Biopharmaceuticals, LLCInventor: Stanley Arthur Kim
-
Patent number: 8119104Abstract: A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.Type: GrantFiled: January 25, 2011Date of Patent: February 21, 2012Inventors: Michael Richard Simon, Mark Andrew Kroenke
-
Publication number: 20120039984Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: ApplicationFiled: July 2, 2009Publication date: February 16, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
-
Patent number: 8101367Abstract: Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.Type: GrantFiled: November 24, 2009Date of Patent: January 24, 2012Assignee: Medical Diagnostic Laboratories, LLCInventors: Tera L. McCool, Chien Chang Loa, Eli Mordechai, Martin E. Adelson
-
Patent number: 8092800Abstract: This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.Type: GrantFiled: March 10, 2006Date of Patent: January 10, 2012Assignee: Istituto Superiore di SanitaInventors: Antonio Cassone, Flavia de Bernardis, Steven Grant, Haiqun Liu
-
Patent number: 8093360Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.Type: GrantFiled: September 28, 2007Date of Patent: January 10, 2012Assignee: Elusys Therapeutics, Inc.Inventor: Leslie S. Casey
-
Patent number: 8071100Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: February 21, 2008Date of Patent: December 6, 2011Assignee: The Unites States of America as represented by the Secretary of Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri